Michael Lahn
Company: iOnctura SA
Job title: Chief Medical Officer
Seminars:
Utilizing Combination Therapies Targeting Diverse TGF-β-Dependent Anti- Fibrotic & Immunosuppressive Mechanisms in Oncology 12:00 pm
Refocusing from mono-directed TGF-β therapies to combination treatments for novel and effective anti-cancer therapies Exploring alternatives to checkpoint inhibitors for novel combination therapies using TGF-β targeted therapies Deep diving into ALK5 inhibitors in conjunction with autotaxin inhibitors to show clinical efficacy New Data!Read more
day: Conference Day One
Avoiding the Pitfalls in Targeting TGF-β to Achieve Better Specificity, Reduced Toxicity & More Effective Treatments 1:01 pm
The pleiotropic nature of TGF-β means that this cytokine is involved in numerous mechanisms and pathways. As a result, non-specific targeting can lead to severe side effects and toxicities. This workshop aims to gain a more complete understanding of the TGF-β pathways that can help explain and avoid unintended toxicities in therapies, with a broader…Read more
day: Pre-Conference Day